MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
AxoGen EBITDA 2011-2026 | AXGN
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA AxoGen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.19 M | 3.18 M | -17.2 M | -26.9 M | -22.7 M | -21.7 M | -28.5 M | -19.6 M | -7.38 M | -7.69 M | -9.02 M | -9.6 M | -9.45 M | -7.49 M | -6.63 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.18 M | -28.5 M | -12.8 M |
Quarterly EBITDA AxoGen
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.33 M | 67 K | - | 1.34 M | 1.23 M | -3.04 M | - | -2.87 M | -6.1 M | -6.63 M | - | -4.09 M | -7.21 M | -10.6 M | - | -4.63 M | -6.52 M | -5.45 M | - | -671 K | -7.94 M | -8.2 M | - | -5.92 M | -7.44 M | -9.99 M | - | -4.64 M | -4.62 M | -4.81 M | - | -1.37 M | -1.34 M | -3.09 M | - | -919 K | -1.44 M | -2.54 M | - | -1.78 M | -2.07 M | -2.5 M | - | -1.69 M | -2.23 M | -2.96 M | - | -2.22 M | -2.15 M | -2.3 M | - | -1.9 M | -1.48 M | -1.89 M | - | -2.41 M | -1.3 M | -827 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.33 M | -10.6 M | -3.31 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aziyo Biologics
AZYO
|
-26.8 M | - | 1.37 % | $ 20.5 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | USA |
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |
 |
Bruker Corporation
BRKR
|
437 M | $ 38.78 | -1.25 % | $ 5.78 K | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | USA |
 |
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | USA |
 |
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | USA |
 |
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
8.53 M | $ 8.15 | 4.22 % | $ 585 M |  Israel |
 |
Second Sight Medical Products
EYES
|
-24.3 M | - | -0.97 % | $ 54.4 M | USA |
 |
AdaptHealth Corp.
AHCO
|
473 M | $ 9.69 | 3.09 % | $ 1.31 B | USA |
 |
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-18 M | $ 4.15 | 4.01 % | $ 155 M |  France |
 |
Electromed
ELMD
|
10.7 M | $ 24.26 | 1.17 % | $ 205 M | USA |
 |
CONMED Corporation
CNMD
|
120 M | $ 43.13 | -0.43 % | $ 1.34 B | USA |
 |
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
FONAR Corporation
FONR
|
9.84 M | $ 18.51 | 0.05 % | $ 121 M | USA |
 |
Apyx Medical Corporation
APYX
|
-16.6 M | $ 3.31 | 4.42 % | $ 115 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | USA |
 |
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Accuray Incorporated
ARAY
|
14 M | $ 0.53 | 0.68 % | $ 54.5 M | USA |
 |
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Medigus Ltd.
MDGS
|
-9.9 M | - | 10.28 % | $ 55.5 M | Israel |
 |
Cytosorbents Corporation
CTSO
|
-15.2 M | $ 0.79 | -1.24 % | $ 43 M | USA |
 |
Align Technology
ALGN
|
753 M | $ 183.14 | 0.27 % | $ 13.7 B | USA |
 |
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | USA |
 |
Inari Medical
NARI
|
-23.4 M | - | - | $ 4.23 B | USA |
 |
Butterfly Network
BFLY
|
-65.5 M | $ 3.99 | 7.7 % | $ 845 M | USA |
 |
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | USA |
 |
Abbott Laboratories
ABT
|
9.49 B | $ 113.59 | 0.01 % | $ 198 B | USA |
 |
NuVasive
NUVA
|
147 M | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
-118 M | - | - | $ 217 M | USA |
 |
InMode Ltd.
INMD
|
86.1 M | $ 13.58 | -0.18 % | $ 878 M | Israel |
 |
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
4.98 B | $ 72.75 | -1.49 % | $ 108 B | USA |
 |
IRadimed Corporation
IRMD
|
22.8 M | $ 105.22 | 0.89 % | $ 1.33 B | USA |
 |
IRIDEX Corporation
IRIX
|
-8.91 M | $ 1.42 | -0.7 % | $ 22.9 M | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.31 | 16.67 % | $ 1.4 M | USA |
 |
Alphatec Holdings
ATEC
|
-4.64 M | $ 13.05 | 0.23 % | $ 1.96 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 85.73 | 0.55 % | $ 50.1 B | USA |